Physician profile
Jack C Yu
NPI 1538270210
$912.35
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $34.69 · 2021: $59.11 · 2022: $403 · 2024: $135 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $238.08 | 2022 | |
| Solventum Corporation | $149.23 | 2024-2025 | Activ.A.C., V.A.C. Granufoam, V.A.C. Veraflo Cleanse Choice |
| Avanos Medical | $147.91 | 2022 | |
| Aroa Biosurgery Incorporated | $147.75 | 2025 | |
| Lemaitre Vascular, INC. | $74.80 | 2019 | |
| Smith+Nephew, INC. | $43.82 | 2019 | |
| Integra Lifesciences Corporation | $28.47 | 2021 | |
| Boston Scientific Corporation | $18.11 | 2020 | |
| Kci USA, INC. | $16.96 | 2022 | |
| Mentor Worldwide LLC | $16.59 | 2021 | |
| Covidien Lp | $16.58 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.